2B78:F:F-iShares Healthcare Innovation UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 6.898

Change

0.00 (0.00)%

Market Cap

N/A

Volume

120.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-04 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.06 (-0.21%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.03 (-0.05%)

USD 116.66B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.06 (-0.10%)

USD 91.05B
SXR8:F iShares Core S&P 500 UCITS ETF..

-1.12 (-0.22%)

USD 85.22B
FRCJ:F UBS MSCI Japan Socially Respon..

+0.05 (+0.24%)

USD 74.74B
EUNL:F iShares Core MSCI World UCITS ..

-0.43 (-0.46%)

USD 72.04B
SXRZ:F iShares VII PLC - iShares Nikk..

+0.55 (+0.24%)

USD 55.89B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.03 (-0.19%)

USD 55.84B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.02 (-0.02%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

-0.07 (-0.08%)

USD 51.63B

ETFs Containing 2B78:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.59% 40% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.59% 38% F 47% F
Trailing 12 Months  
Capital Gain -22.09% 9% A- 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.09% 8% B- 26% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -5.25% 14% F 30% F
Dividend Return -5.25% 13% F 27% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.51% 58% F 81% B-
Risk Adjusted Return -49.97% 21% F 23% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.